Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022
[267 Pages Report] The global cancer biomarkers market is accounted for USD 10.31 billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 billion by 2022 during the forecast period. Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using Genomics and proteomics.
Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process and have formed strategic alliances for sharing technology for biomarker applications in large-stage clinical trials are fueling the growth of this market. The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022.
Cancer biomarkers Market Dynamics
Drivers
- Technological advancements
- Rising incidence of cancer
- Enhanced accuracy and speed of diagnosis
- Increasing use of cancer biomarkers in drug discovery and development
- Increasing research on cancer biomarkers
Restraint
- Poorly suited regulatory and reimbursement systems
- High capital investment and low benefit-cost ratio
- Technical issues related to sample collection and storage
Opportunities
- Personalized medicine
- Companion diagnostics
- Emerging economies
Challenges
- Proving clinical validity and utility of biomarker-based tests leading to their insufficient acceptance
Due to technological advancements, the process of discovery and development of novel biomarkers has been simplified to a great extent.
Advancements in omics technologies enable faster acquisition of genomic, proteomic, and metabolomic data and its integration with clinical trial data using advanced bioinformatics software. The omics revolution in the last decade has increased the applications of biomarkers in biomedical research. Also, developments in high-throughput genomic technologies are facilitating the identification and analysis of mutations and polymorphisms in key genes. This has helped in the expansion of the spectrum of available genomic biomarkers. For instance, researchers at the Mayo Clinic have identified the role of mutations in the SPOP gene on the development of resistance to BET. With these advancements, the number of available genomic biomarkers for the detection of cancer is expected to increase.
Many major global market players are focusing on introducing innovative products in order to increase the efficiency and speed of biomarker discovery. For instance, in January 2016, Illumina (US) launched the MiniSeq benchtop sequencer. This system reduces the cost of sequencing as well as the time taken for output delivery, which enables high-throughput laboratories to increase their productivity. Similarly, in March 2017, QIAGEN N.V. announced the launch of its ipsogen JAK2 RGQ PCR Kit for the detection of the JAK2 V617F/G1849T allele in a group of blood cancers in the US. In addition, advancements in arrays and Proteomics technologies have addressed the challenges in the identification and understanding of functions and interactions of various proteins. As a result of these technological advancements, the process of discovery and development of novel biomarkers has been simplified to a great extent
Cancer biomarkers Market : Objectives of the Study
- To define, describe, and segment the global market by type, cancer type, profiling technology, application, and region
- To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the global market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)
- To profile key players in the market and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as acquisitions, product launches, expansions, and other developments in the cancer biomarkers market
Cancer biomarkers Market : Research Methodology
Top-down and bottom-up approaches were used to validate the size of the global Patient Lateral Transfer market and estimate the size of other dependent submarkets. Various secondary sources such as World Health Organization, World Bank, Centers for Disease Control and Prevention, National Institutes of Health, Canadian Institute of Health Information, National Cancer Institute, European Association for Cancer Research, Australian Cancer Research Foundation (ACRF), GLOBOCAN 2012, Cancer Journal for Clinicians, World Bank, U.S. Census Bureau, Canadian Institute of Health Information, databases, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
The market is dominated by established players such as Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Abbott Laboratories, Qiagen N.V., Merck & Co., Becton Dickinson and Company, and Hologic.
Cancer biomarkers Market : Target Audience:
- Manufacturing companies of diagnostics kits and imaging instrument providers
- Biomarkers assay and reagent manufacturers, vendors, and distributors
- Contract research organizations (CROs)
- Companies offering platforms/technologies for cancer diagnosis
- Market research and consulting firms
- Venture capitalists and investors
Cancer biomarkers Market : Scope of the Report
- The market study doesnt cover the market size in terms of volume
- Some companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenue for those companies are not included in this report
- Company developments not reported in the public domain are not included in this report
|
Particular |
|
|
Historical Years |
2015 |
|
Base Year |
2016 |
|
Estimated Year |
2017-e |
|
Forecast Period |
2017-e2022-p |
|
Revenue Currency |
USD |
Market Segmentation
This research report categorizes the cancer biomarker market on the basis of biomarker type, cancer type, profiling technology, application, and region.
<Global Cancer Biomarker Market, By Type
- Protein Biomarker
- Genetic Biomarker
- Other Cancer Biomarkers (cell, viral, and carbohydrate biomarkers)
Global Cancer Biomarker Market, By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Non-hodgkins lymphoma
- Melanoma
- Leukemia
- Thyroid Cancer
- Bladder Cancer
- Kidney Cancer
- Other Cancers (multiple myeloma, cervical, central nervous system cancer, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancer
Global Cancer Biomarker Market, By Profiling Technology
- Omics Technologies
- Genomics
- Proteomics
- Other Omics Technology
- Imaging Technologies
- Ultrasound
- CT
- MRI
- PET
- Mammography
- Immunoassays
- Cytogenetics
- In Situ Hybridization
- Other Cytogenetics
- Bioinformatics
Global Cancer Biomarker Market, By Application
- Diagnostics
- Research
- Prognostics
- Risk Assessment
- Other Applications (personalized medicine, surrogate endpoints, and therapeutics)
Global Cancer Biomarker market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (ROE)
- Asia Pacific (APAC)
- Japan
- Rest of Asia Pacific (ROAPAC)
- Rest of the World (ROW)
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
- Company Information, detailed analysis and profiling of additional market players (Up to 5)
The global cancer biomarker market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022.
Major factors driving the growth of the market are rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, the high cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection are restricting the growth of this market. In this report, the global cancer biomarker market is segmented on the basis of biomarker type, cancer type, profiling technology, application, and region.
Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.
The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkins lymphoma, kidney, and other cancers. In 2017, the breast cancer segment is expected to account for the largest share of the global market by cancer type. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.
On the basis of biomarker type, the market segmented into protein biomarker, genetic biomarker, and other biomarkers. In 2017, the protein biomarkers segment is expected to account for the largest share of the global market. The large share of this segment is mainly attributed to the tremendous potential of protein biomarkers in cancer detection, diagnostics, prognostics, and clinical & therapeutic applications; and low cost of the protein biomarker tests as compared to genetic biomarker tests. The increasing focus of pharmaceutical companies towards the discovery of protein biomarkers is further expected to fuel the growth of this market during the forecast period.
On the basis of application, the market is classified into diagnostics, research and development, prognostics, risk assessment, and other applications. In 2017, the diagnostics segment is expected to account for largest share of the global cancer biomarkers market. The large share of this segment is mainly attributed to the rising incidences of cancer, increased awareness and acceptance of diagnostic tests, technological advancements, and the need for early-stage cancer diagnosis.
The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. While North America (comprising the U.S. and Canada) is expected to account for the largest share of the global cancer biomarker market in 2017. The Asia-Pacific cancer biomarker market, particularly in China, Japan, and India is expected to witness high growth in the forecast period. Factors such as rising incidence of cancer, increasing use of biomarker tests for diagnostic purposes, expansions of major pharmaceutical companies in emerging Asian economies, and government support to research institutes and universities are further drive the growth of this market in the APAC region.
Rising adoption of genomics technologies in drug discovery and clinical applications such as NGS and PCR are driving the growth of cancer biomarker market.
Next generation sequencing (NGS)
Sequencing is the process of determining the precise order of nucleotides in a DNA/RNA sample. The advent of rapid sequencing methods has greatly enhanced biological and medical research and the discovery of biomarkers. Next-generation Sequencing (NGS) is one of the most significant developments in genomics technologies with regards to cancer biomarker discovery, diagnostics, and prognostics. It has advanced the biomarker discovery process by accelerating the timeline of sequencing as R&D efforts are no longer bound to a single gene or small gene panels. Through massively parallel sequencing, this technology brings about faster identification of genetic diseases in specific populations or tissue types
Polymerase chain reaction (PCR)
Polymerase Chain Reaction (PCR) is a laboratory technique used to make multiple copies of a segment of DNA. It is very precise and can be used to amplify or copy a specific DNA target from a mixture of DNA molecules. It enables the detection of minimal residual disease and also detects cancer with genetic abnormalities. PCR can help define subgroups of patients that are suitable candidates for anti-cancer therapies. PCR-based diagnostic kits are used to detect several biomarkers such as B-Raf, Epidermal Growth Factor Receptor (EGFR), and Kristen Rat Sarcoma (KRAS), among others, to access specific mutations in clinical trial laboratories. They aid in selecting the right candidates in clinical trials for treatment with tailored drugs.
Critical questions the report answers:
- Where will all these technologies take the industry in the mid to long term?
- What are the segments which offers lucrative opportunity in cancer biomarker market?
Significant capital investments are required for the discovery, development, and validation of biomarkers. This is a major factor restraining the growth of the biomarkers market and other related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and personalized medicine. The discovery of candidate biomarkers far outpaces the current ability to validate them. In addition, due to the high drug attrition in clinical trials (with almost 30% drugs failing in phase III), diagnostics manufacturers are facing significant financial challenges. To gain approval for an IVD from regulators, manufacturers need successful phase III clinical trials, which depend on well-validated biomarker tests. Huge investments are required to run clinical trials and address stringent regulatory requirements, which not only affects the ability of small companies to develop biomarkers but also severely affects innovation.
The cancer biomarkers market is dominated by established players such as Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Abbott Laboratories, Qiagen N.V., Merck & Co., Becton Dickinson and Company, and Hologic.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 23)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. - 26)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.2.1 Secondary Sources
2.2.1.1 Key Industry Insights
2.3 Assumptions for the Study
3 Executive Summary (Page No. - 34)
4 Premium Insights (Page No. - 38)
4.1 Cancer Biomarkers: Market Snapshot
4.2 Asia Pacific Market, By Profiling Technology and Application
4.3 Cancer Biomarkers Market Share, By Cancer Type, 2017 vs 2022
4.4 Global Market for Cancer Biomarkers: Share, By Biomarker Type, 2015 to 2022
4.5 Market, By Region
5 Market Overview (Page No. - 42)
5.1 Introduction
5.1.1 Drivers
5.1.1.1 Technological Advancements
5.1.1.2 Rising Incidence of Cancer
5.1.1.3 Increasing Use of Cancer Biomarkers in Drug Discovery and Development
5.1.1.4 Increasing Research on Cancer Biomarkers
5.1.2 Restraints
5.1.2.1 Unfavorable Regulatory and Reimbursement Scenario
5.1.2.2 High Capital Investment and Low Benefit-Cost Ratio
5.1.2.3 Technical Issues Related to Sample Collection and Storage
5.1.3 Opportunities
5.1.3.1 Personalized Medicine
5.1.3.2 Companion Diagnostics
5.1.3.3 Emerging Economies
5.1.4 Challenges
5.1.4.1 Proving the Clinical Validity and Utility of Biomarker-Based Tests
6 Cancer Biomarkers Market, By Biomarker Type (Page No. - 48)
6.1 Introduction
6.2 Protein Biomarkers
6.3 Genetic Biomarkers
6.3.1 Lung Cancer
6.3.2 Colorectal Cancer
6.3.3 Breast Cancer
6.3.4 Prostate Cancer
6.3.5 Leukemia
6.4 Other Cancer Biomarkers
7 Market, By Cancer Type (Page No. - 63)
7.1 Introduction
7.2 Breast Cancer
7.3 Lung Cancer
7.4 Colorectal Cancer
7.5 Prostate Cancer
7.6 Non-Hodgkins Lymphoma
7.7 Melanoma
7.8 Leukemia
7.9 Thyroid Cancer
7.10 Bladder Cancer
7.11 Kidney Cancer
7.12 Other Cancer Types
8 Market, By Profiling Technology (Page No. - 89)
8.1 Introduction
8.1.1 Omics Technologies
8.1.2 Proteomics
8.1.3 Genomics
8.1.3.1 Next-Generation Sequencing (NGS)
8.1.3.2 Polymerase Chain Reaction (PCR)
8.1.4 Other Omics Technologies
8.2 Imaging Technologies
8.2.1 Ultrasound
8.2.2 Computed Tomography (Ct)
8.2.3 Magnetic Resonance Imaging (Mri)
8.2.4 Positron Emission Tomography (Pet)
8.2.5 Mammography
8.3 Immunoassays
8.4 Cytogenetics
8.4.1 in Situ Hybridization (Ish)
8.4.2 Other Cytogenetics-Based Tests
8.5 Bioinformatics
9 Cancer Biomarkers Market, By Application (Page No. - 133)
9.1 Introduction
9.2 Diagnostics
9.3 Research and Development
9.4 Prognostics
9.5 Risk Assessment
9.6 Other Applications
10 Market, By Region (Page No. - 146)
10.1 Introduction
10.2 North America
10.2.1 Us
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 Uk
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe (RoE)
10.4 Asia Pacific
10.4.1 Japan
10.4.2 Rest of APAC
10.5 Rest of the World (RoW)
11 Competitive Landscape (Page No. - 208)
11.1 Market Ranking Analysis, 2016
12 Company Profiles (Page No. - 209)
(Business Overview, Products Offered, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments.)*
12.1 Thermo Fisher Scientific
12.2 Bio-Rad Laboratories
12.3 Roche Diagnostics
12.4 Qiagen N.V.
12.5 Illumina
12.6 GE Healthcare
12.7 Agilent Technologies
12.8 Biomιrieux SA
12.9 Merck & Co.
12.10 Abbott Laboratories
12.11 Becton, Dickinson and Company
12.12 Danaher Corporation
12.13 Myriad Genetics
12.14 Sysmex Corporation
12.15 Hologic
12.16 Quest Diagnostics
*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key Relationships Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 257)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (268 Tables)
Table 1 Cancer Biomarkers Market, By Biomarker Type, 20152022 (USD Million)
Table 2 Global Protein Market, By Region, 20152022 (USD Million)
Table 3 North America: Protein Market, By Country, 20152022 (USD Million)
Table 4 Europe: Protein Market, By Country/Region, 20152022 (USD Million)
Table 5 Asia Pacific: Protein Market, By Country/Region, 20152022 (USD Million)
Table 6 Global Genetic Market, By Region, 20152022 (USD Million)
Table 7 North America: Genetic Market, By Country, 20152022 (USD Million)
Table 8 Europe: Genetic Cancer Biomarkers Market, By Country/Region, 20152022 (USD Million)
Table 9 Asia Pacific: Genetic Market, By Country/Region, 20152022 (USD Million)
Table 10 Global Other Market, By Region, 20152022 (USD Million)
Table 11 North America: Other Market, By Country, 20152022 (USD Million)
Table 12 Europe: Other Market, By Country/Region, 20152022 (USD Million)
Table 13 Asia Pacific: Other Market, By Country/Region, 20152022 (USD Million)
Table 14 Global Cancer Biomarkers Market, By Cancer Type, 20152022 (USD Million)
Table 15 Global Breast Market, By Region, 20152022 (USD Million)
Table 16 North America: Breast Market, By Country, 20152022 (USD Million)
Table 17 Europe: Breast Market, By Country, 20152022 (USD Million)
Table 18 Asia Pacific: Breast Market, By Country, 20152022 (USD Million)
Table 19 Global Lung Market, By Region, 20152022 (USD Million)
Table 20 North America: Lung Market, By Country, 20152022 (USD Million)
Table 21 Europe: Lung Market, By Country, 20152022 (USD Million)
Table 22 Asia Pacific: Lung Market, By Country, 20152022 (USD Million)
Table 23 Global Colorectal Market, By Region, 20152022 (USD Million)
Table 24 North America: Colorectal Cancer Biomarkers Market, By Country, 20152022 (USD Million)
Table 25 Europe: Colorectal Market, By Country, 20152022 (USD Million)
Table 26 Asia Pacific: Colorectal Market, By Country, 20152022 (USD Million)
Table 27 Global Prostate Market, By Region, 20152022 (USD Million)
Table 28 North America: Prostate Market, By Country, 20152022 (USD Million)
Table 29 Europe: Prostate Market, By Country, 20152022 (USD Million)
Table 30 Asia Pacific: Prostate Market, By Country, 20152022 (USD Million)
Table 31 Global Non-Hodgkins Lymphoma Biomarkers Market, By Region, 20152022 (USD Million)
Table 32 North America: Non-Hodgkins Lymphoma Biomarkers Market, By Country, 20152022 (USD Million)
Table 33 Europe: Non-Hodgkins Lymphoma Biomarkers Market, By Country, 20152022 (USD Million)
Table 34 Asia Pacific: Non-Hodgkins Lymphoma Biomarkers Market, By Country, 20152022 (USD Million)
Table 35 Global Melanoma Biomarkers Market, By Region, 20152022 (USD Million)
Table 36 North America: Melanoma Biomarkers Market, By Country, 20152022 (USD Million)
Table 37 Europe: Melanoma Biomarkers Market, By Country, 20152022 (USD Million)
Table 38 Asia Pacific: Melanoma Biomarkers Market, By Country, 20152022 (USD Million)
Table 39 Global Leukemia Biomarkers Market, By Region, 20152022 (USD Million)
Table 40 North America: Leukemia Biomarkers Market, By Country, 20152022 (USD Million)
Table 41 Europe: Leukemia Biomarkers Market, By Country, 20152022 (USD Million)
Table 42 Asia Pacific: Leukemia Biomarkers Market, By Country, 20152022 (USD Million)
Table 43 Global Thyroid Cancer Biomarkers Market, By Region, 20152022 (USD Million)
Table 44 North America: Thyroid Market, By Country, 20152022 (USD Million)
Table 45 Europe: Thyroid Market, By Country, 20152022 (USD Million)
Table 46 Asia Pacific: Thyroid Market, By Country, 20152022 (USD Million)
Table 47 Global Bladder Market, By Region, 20152022 (USD Million)
Table 48 North America: Bladder Market, By Country, 20152022 (USD Million)
Table 49 Europe: Bladder Market, By Country, 20152022 (USD Million)
Table 50 Asia Pacific: Bladder Market, By Country, 20152022 (USD Million)
Table 51 Global Kidney Market, By Region, 20152022 (USD Million)
Table 52 North America: Kidney Market, By Country, 20152022 (USD Million)
Table 53 Europe: Kidney Market, By Country, 20152022 (USD Million)
Table 54 Asia Pacific: Kidney Market, By Country, 20152022 (USD Million)
Table 55 Global Other Market, By Region, 20152022 (USD Million)
Table 56 North America: Other Market, By Country, 20152022 (USD Million)
Table 57 Europe: Other Cancer Biomarkers Market, By Country, 20152022 (USD Million)
Table 58 Asia Pacific: Other Market, By Country, 20152022 (USD Million)
Table 59 Market, By Profiling Technology, 20152022 (USD Million)
Table 60 Market for Omics Technologies, By Type, 20152022 (USD Million)
Table 61 Market for Omics Technologies, By Region, 20152022 (USD Million)
Table 62 North America: Market for Omics Technologies, By Country, 20152022 (USD Million)
Table 63 Europe: Market for Omics Technologies, By Country, 20152022 (USD Million)
Table 64 Asia Pacific: Market for Omics Technologies, By Country, 20152022 (USD Million)
Table 65 Market for Proteomics, By Region, 20152022 (USD Million)
Table 66 North America: Market for Proteomics, By Country, 20152022 (USD Million)
Table 67 Europe: Market for Proteomics, By Country, 20152022 (USD Million)
Table 68 Asia Pacific: Market for Proteomics, By Country, 20152022 (USD Million)
Table 69 Market for Genomics, By Type, 20152022 (USD Million)
Table 70 Market for Genomics, By Region, 20152022 (USD Million)
Table 71 North America: Market for Genomics, By Country, 20152022 (USD Million)
Table 72 Europe: Market for Genomics, By Country, 20152022 (USD Million)
Table 73 Asia Pacific: Market for Genomics, By Country, 20152022 (USD Million)
Table 74 Market for NGS, By Region, 20152022 (USD Million)
Table 75 North America: Market for NGS, By Country, 20152022 (USD Million)
Table 76 Europe: Market for NGS, By Country, 20152022 (USD Million)
Table 77 Asia Pacific: Market for NGS, By Country, 20152022 (USD Million)
Table 78 Cancer Biomarkers Market for PCR, By Region, 20152022 (USD Million)
Table 79 North America: Market for PCR, By Country, 20152022 (USD Million)
Table 80 Europe: Market for PCR, By Country, 20152022 (USD Million)
Table 81 Asia Pacific: Market for PCR, By Country, 20152022 (USD Million)
Table 82 Market for Other Omics Technologies, By Region, 20152022 (USD Million)
Table 83 North America: Market for Other Omics Technologies, By Country, 20152022 (USD Million)
Table 84 Europe: Market for Other Omics Technologies, By Country, 20152022 (USD Million)
Table 85 Asia Pacific: Market for Other Omics Technologies, By Country, 20152022 (USD Million)
Table 86 Market for Imaging Technologies, By Type, 20152022 (USD Million)
Table 87 Market for Imaging Technologies, By Region, 20152022 (USD Million)
Table 88 North America: Market for Imaging Technologies, By Country, 20152022 (USD Million)
Table 89 Europe: Market for Imaging Technologies, By Country/Region, 20152022 (USD Million)
Table 90 Asia Pacific: Market for Imaging Technologies, By Country, 20152022 (USD Million)
Table 91 Market for Ultrasound, By Region, 20152022 (USD Million)
Table 92 North America: Market for Ultrasound, By Country, 20152022 (USD Million)
Table 93 Europe: Market for Ultrasound, By Country, 20152022 (USD Million)
Table 94 Asia Pacific: Market for Ultrasound, By Country, 20152022 (USD Million)
Table 95 Market for Ct, By Region, 20152022 (USD Million)
Table 96 North America: Market for Ct, By Country, 20152022 (USD Million)
Table 97 Europe: Market for Ct, By Country, 20152022 (USD Million)
Table 98 Asia Pacific: Market for Ct, By Country, 20152022 (USD Million)
Table 99 Cancer Biomarkers Market for Mri, By Region, 20152022 (USD Million)
Table 100 North America: Market for Mri, By Country, 20152022 (USD Million)
Table 101 Europe: Market for Mri, By Country, 20152022 (USD Million)
Table 102 Asia Pacific: Market for Mri, By Country, 20152022 (USD Million)
Table 103 Market for Pet, By Region, 20152022 (USD Million)
Table 104 North America: Market for Pet, By Country, 20152022 (USD Million)
Table 105 Europe: Market for Pet, By Country, 20152022 (USD Million)
Table 106 Asia Pacific: Market for Pet, By Country, 20152022 (USD Million)
Table 107 Market for Mammography, By Region, 20152022 (USD Million)
Table 108 North America: Market for Mammography, By Country, 20152022 (USD Million)
Table 109 Europe: Market for Mammography, By Country, 20152022 (USD Million)
Table 110 Asia Pacific: Market for Mammography, By Country, 20152022 (USD Million)
Table 111 Cancer Biomarkers Market for Immunoassays, By Region, 20152022 (USD Million)
Table 112 North America: Market for Immunoassays, By Country, 20152022 (USD Million)
Table 113 Europe: Market for Immunoassays, By Country, 20152022 (USD Million)
Table 114 Asia Pacific: Market for Immunoassays, By Country, 20152022 (USD Million)
Table 115 Market for Cytogenetics, By Region, 20152022 (USD Million)
Table 116 North America: Market for Cytogenetics, By Country, 20152022 (USD Million)
Table 117 Europe: Market for Cytogenetics, By Country, 20152022 (USD Million)
Table 118 Asia Pacific: Market for Cytogenetics, By Country, 20152022 (USD Million)
Table 119 Market for Ish, By Region, 20152022 (USD Million)
Table 120 North America: Market for Ish, By Country, 20152022 (USD Million)
Table 121 Europe: Market for Ish, By Country, 20152022 (USD Million)
Table 122 Asia Pacific: Market for Ish, By Country, 20152022 (USD Million)
Table 123 Market for Other Cytogenetics-Based Tests, By Region, 20152022 (USD Million)
Table 124 North America: Market for Other Cytogenetics-Based Tests, By Country, 20152022 (USD Million)
Table 125 Europe: Market for Other Cytogenetics-Based Tests, By Country, 20152022 (USD Million)
Table 126 Asia Pacific: Market for Other Cytogenetics-Based Tests, By Country, 20152022 (USD Million)
Table 127 Global Market for Bioinformatics, By Region, 20152022 (USD Million)
Table 128 North America: Market for Bioinformatics, By Country, 20152022 (USD Million)
Table 129 Europe: Market for Bioinformatics, By Country, 20152022 (USD Million)
Table 130 Asia Pacific: Market for Bioinformatics, By Country, 20152022 (USD Million)
Table 131 Global Cancer Biomarkers Market, By Application, 20152022 (USD Million)
Table 132 Global Market for Diagnostics, By Region, 20152022 (USD Million)
Table 133 North America: Market for Diagnostics, By Country, 20152022 (USD Million)
Table 134 Europe: Market for Diagnostics, By Country, 20152022 (USD Million)
Table 135 Asia Pacific: Market for Diagnostics, By Country, 20152022 (USD Million)
Table 136 Global Market for Research and Development, By Region, 20152022 (USD Million)
Table 137 North America: Market for Research and Development, By Country, 20152022 (USD Million)
Table 138 Europe: Market for Research and Development, By Country, 20152022 (USD Million)
Table 139 Asia Pacific: Market for Research and Development, By Country, 20152022 (USD Million)
Table 140 Global Market for Prognostics, By Region, 20152022 (USD Million)
Table 141 North America: Market for Prognostics, By Country, 20152022 (USD Million)
Table 142 Europe: Market for Prognostics, By Country, 20152022 (USD Million)
Table 143 Asia Pacific: Market for Prognostics, By Country, 20152022 (USD Million)
Table 144 Global Cancer Biomarkers Market for Risk Assessment, By Region, 20152022 (USD Million)
Table 145 North America: Market for Risk Assessment, By Country, 20152022 (USD Million)
Table 146 Europe: Market for Risk Assessment, By Country, 20152022 (USD Million)
Table 147 Asia Pacific: Market for Risk Assessment, By Country, 20152022 (USD Million)
Table 148 Global Market for Other Applications, By Region, 20152022 (USD Million)
Table 149 North America: Market for Other Applications, By Country, 20152022 (USD Million)
Table 150 Europe: Market for Other Applications, By Country, 20152022 (USD Million)
Table 151 Asia Pacific: Market for Other Applications, By Country, 20152022 (USD Million)
Table 152 Global Market, By Region, 20152022 (USD Million)
Table 153 North America: Market, By Country, 20152022 (USD Million)
Table 154 North America: Market, By Cancer Type, 20152022 (USD Million)
Table 155 North America: Cancer Biomarkers Market, By Biomarker Type, 20152022 (USD Million)
Table 156 North America: Market, By Profiling Technology, 20152022 (USD Million)
Table 157 North America: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 158 North America: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 159 North America: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 160 North America: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 161 North America: Market, By Application, 20152022 (USD Million)
Table 162 US: Market, By Cancer Type, 20152022 (USD Million)
Table 163 US: Market, By Biomarker Type, 20152022 (USD Million)
Table 164 US: Market, By Profiling Technology, 20152022 (USD Million)
Table 165 US: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 166 US: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 167 US: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 168 US: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 169 US: Market, By Application, 20152022 (USD Million)
Table 170 Canada: Market, By Cancer Type, 20152022 (USD Million)
Table 171 Canada: Market, By Biomarker Type, 20152022 (USD Million)
Table 172 Canada: Market, By Profiling Technology, 20152022 (USD Million)
Table 173 Canada: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 174 Canada: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 175 Canada: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 176 Canada: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 177 Canada: Market, By Application, 20152022 (USD Million)
Table 178 Europe :Cancer Biomarkers Market, By Country, 20152022 (USD Million)
Table 179 Europe: Market, By Cancer Type, 20152022 (USD Million)
Table 180 Europe: Market, By Biomarker Type, 20152022 (USD Million)
Table 181 Europe: Market, By Profiling Technology, 20152022 (USD Million)
Table 182 Europe: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 183 Europe: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 184 Europe: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 185 Europe: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 186 Europe: Market, By Application, 20152022 (USD Million)
Table 187 Germany: Market, By Cancer Type, 20152022 (USD Million)
Table 188 Germany: Market, By Biomarker Type, 20152022 (USD Million)
Table 189 Germany: Market, By Profiling Technology, 20152022 (USD Million)
Table 190 Germany: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 191 Germany: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 192 Germany: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 193 Germany: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 194 Germany: Market, By Application, 20152022 (USD Million)
Table 195 UK: Market, By Cancer Type, 20152022 (USD Million)
Table 196 UK: Market, By Biomarker Type, 20152022 (USD Million)
Table 197 UK: Cancer Biomarkers Market, By Profiling Technology, 20152022 (USD Million)
Table 198 UK: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 199 UK: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 200 UK: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 201 UK: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 202 UK: Market, By Application , 20152022 (USD Million)
Table 203 France: Market, By Cancer Type, 20152022 (USD Million)
Table 204 France: Market, By Biomarker Type, 20152022 (USD Million)
Table 205 France: Market, By Profiling Technology, 20152022 (USD Million)
Table 206 France: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 207 France: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 208 France: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 209 France: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 210 France: Market, By Application, 20152022 (USD Million)
Table 211 Italy: Cancer Biomarkers Market, By Cancer Type, 20152022 (USD Million)
Table 212 Italy: Market, By Biomarker Type, 20152022 (USD Million)
Table 213 Italy: Market, By Profiling Technology, 20152022 (USD Million)
Table 214 Italy: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 215 Italy: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 216 Italy: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 217 Italy: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 218 Italy: Market, By Application, 20152022 (USD Million)
Table 219 Spain: Market, By Cancer Type, 20152022 (USD Million)
Table 220 Spain: Market, By Biomarker Type, 20152022 (USD Million)
Table 221 Spain: Market, By Profiling Technology, 20152022 (USD Million)
Table 222 Spain: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 223 Spain: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 224 Spain: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 225 Spain: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 226 Spain: Market, By Application, 20152022 (USD Million)
Table 227 RoE: Cancer Biomarkers Market, By Cancer Type, 20152022 (USD Million)
Table 228 RoE: Market, By Type, 20152022 (USD Million)
Table 229 RoE: Market, By Profiling Technology, 20152022 (USD Million)
Table 230 RoE: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 231 RoE: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 232 RoE: Imaging Technologies Market, 20152022 (USD Million)
Table 233 RoE: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 234 RoE: Market, By Application, 20152022 (USD Million)
Table 235 Asia Pacific: Cancer Biomarkers Market, By Country, 20152022 (USD Million)
Table 236 Asia Pacific: Market, By Cancer Type, 20152022 (USD Million)
Table 237 Asia Pacific: Market, By Type, 20152022 (USD Million)
Table 238 Asia Pacific: Market, By Profiling Technology, 20152022 (USD Million)
Table 239 Asia Pacific: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 240 Asia Pacific: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 241 Asia Pacific: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 242 Asia Pacific: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 243 Asia Pacific: Market, By Application, 20152022 (USD Million)
Table 244 Japan: Cancer Biomarkers Market, By Cancer Type, 20152022 (USD Million)
Table 245 Japan: Market, By Type, 20152022 (USD Million)
Table 246 Japan: Market, By Profiling Technology, 20152022 (USD Million)
Table 247 Japan: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 248 Japan: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 249 Japan: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 250 Japan: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 251 Japan: Market, By Application, 20152022 (USD Million)
Table 252 Rest of APAC: Market, By Cancer Type, 20152022 (USD Million)
Table 253 Rest of APAC: Market, By Biomarker Type, 20152020 (USD Million)
Table 254 Rest of APAC: Market, By Profiling Technology, 20152022 (USD Million)
Table 255 Rest of APAC: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 256 Rest of APAC: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 257 Rest of APAC: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 258 Rest of APAC: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 259 Rest of APAC: Market, By Application, 20152022 (USD Million)
Table 260 RoW: Cancer Biomarkers Market, By Cancer Type, 20152022 (USD Million)
Table 261 RoW: Market, By Type, 20152022 (USD Million)
Table 262 RoW: Market, By Profiling Technology, 20152022 (USD Million)
Table 263 RoW: Omics Technologies Market, By Type, 20152022 (USD Million)
Table 264 RoW: Genomics Technologies Market, By Type, 20152022 (USD Million)
Table 265 RoW: Imaging Technologies Market, By Type, 20152022 (USD Million)
Table 266 RoW: Cytogenetics Market, By Type, 20152022 (USD Million)
Table 267 RoW: Market, By Application, 20152022 (USD Million)
Table 268 Rank of Companies in the Global Cancer Biomarkers Market, 2016
List of Figures (37 Figures)
Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation
Figure 6 Cancer Biomarker Market, By Cancer Type, 2017 vs 2022 (USD Million)
Figure 7 Cancer Biomarker Market, By Biomarker Type, 2017 vs 2022 (USD Million)
Figure 8 Cancer Biomarker Market, By Application, 2017 vs 2022 (USD Million)
Figure 9 Cancer Biomarker Market, By Profiling Technology, 2017 vs 2022 (USD Million)
Figure 10 Geographical Snapshot of the Cancer Biomarker Market
Figure 11 Technological Advancement is A Major Driver for the Cancer Biomarkers Market Growth in 2017
Figure 12 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 Genetic Biomarkers to Register the Highest CAGR in the Forecast Period
Figure 14 Mutation Rate of Cell Surface Receptor Biomarkers in Breast Tumor
Figure 15 Global Market, By Cancer Type
Figure 16 Omics Technologies Will Continue to Dominate the Global Market in 2022
Figure 17 Diagnostics Application Segment to Dominate the Market in 2017
Figure 18 Market: Geographic Snapshot (20172022)
Figure 19 North America Market Snapshot
Figure 20 Europe Market Snapshot
Figure 21 Asia Pacific Market Snapshot
Figure 22 Thermo Fisher Scientific: Company Snapshot (2016)
Figure 23 Bio-Rad Laboratories: Company Snapshot (2016)
Figure 24 Roche Diagnostics: Company Snapshot (2016)
Figure 25 Qiagen N.V.: Company Snapshot (2016)
Figure 26 Illumina: Company Snapshot (2016)
Figure 27 GE Healthcare: Company Snapshot (2016)
Figure 28 Agilent Technologies: Company Snapshot (2016)
Figure 29 Biomιrieux SA: Company Snapshot (2016)
Figure 30 Merck & Co.Inc.: Company Snapshot (2016)
Figure 31 Abbott Laboratories: Company Snapshot (2016)
Figure 32 Becton, Dickinson and Company : Company Snapshot (2016)
Figure 33 Danaher Corporation: Company Snapshot (2016)
Figure 34 Myriad Genetics Inc.: Company Snapshot (2016)
Figure 35 Sysmex Corporation: Company Snapshot (2016)
Figure 36 Hologic: Company Snapshot (2016)
Figure 37 Quest Diagnostics: Company Snapshot (2016)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cancer Biomarkers Market